about
NK cells in therapy of cancerMyeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platformsOutcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells.Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasAllogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia.Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumabImpact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting.A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT.Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation.Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for LymphomaThe addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialUnrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survivalComparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.Hematopoietic cell transplantation for Waldenström macroglobulinemia.Clinical utility of natural killer cells in cancer therapy and transplantation.Role of allogeneic stem cell transplantation in mantle cell lymphoma.Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin eraDiffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions.Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma.Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.Vancomycin plus imipenem ceftazidime or ciprofloxacin in second line therapy in patients with febrile neutropenia not responding to first line therapy.Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.Successful treatment of two cases of classical Hodgkin lymphoma-associated hemophagocytic lymphohistiocyosis with R-CEPP.Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes.Deferring allogeneic transplantation for adult acute lymphoblastic leukemia: is there a second chance?
P50
Q28242241-F604AF20-4F21-41E9-822A-B93DDF7582CDQ33705051-E0FB1C75-A48D-4F29-A3E4-6E3BEF4FB78FQ33766616-38FC6DE0-9C67-49D2-8821-5034A9DB4BF5Q33798412-316054D0-C933-435D-B910-709CFCE9F050Q33850163-04E17B3C-F8BF-4A50-A187-ECCB87C87D2EQ35029453-71F0586E-13AF-4DDC-8118-6D62A712CD90Q35093521-8D60EBCD-8044-4562-8431-7EC85EEB34BAQ35108791-C40BC0C2-63B8-47BE-AFC5-043B2EE94C11Q35129411-5A8AA624-CC6D-4D80-A859-00F282ECC37EQ36021100-3923FA72-983E-4D65-BB5A-9340DE4AF44AQ36092009-76BB1E89-E608-4C40-97DD-024F30AE872EQ36248964-F5BC447C-C4B8-492D-8D62-D3C8675E7A0EQ36264884-E2FDB9E0-5BD5-44F8-B2BA-7E4B1FFAC803Q36488188-344F9301-AFD6-4F9C-954D-1AFA7392347CQ36580520-B4E9CCD1-6CE9-421E-89AC-91C4FDF8458EQ36580547-1F3A91F8-545B-46BF-93B7-A20405D4FDAAQ36634466-4FE5D83F-1099-41DD-BEF0-6B2453874AEDQ36734547-E1BF4431-D501-4AC7-8384-2B95143BC609Q36781786-439FC1B9-E48F-4FE3-8941-028BA60A39F5Q37178329-BB613736-2E7F-487C-83EA-C4F200D97666Q37675281-2A0FDEC4-07DE-44E6-B715-3E03914F90C8Q37875673-F82FB78E-81BD-46BA-BFEA-7AFAEAF498A8Q38195120-3A14823D-F20C-44A6-862C-76675783CB96Q38242980-5172E462-D5D4-4118-9E75-CE70449A6972Q38386440-F5A10BA7-F1F0-4634-8087-AF8CB48D8E77Q38669334-3B968356-08B1-4205-9173-AB70D6C2F937Q38727095-D572C571-E77F-415B-B52A-4709BE36743AQ38843692-0542C8E8-5512-4BDE-B2FC-B14346DBDEE9Q38992200-E309A4F2-671E-4087-A309-3E125A291238Q39158429-AD447B56-2A04-4911-A12E-C7E4BFDFB94DQ39891171-A80BA347-1B7C-485E-AF56-D64ECA2393EBQ40080086-585743B1-EECF-4596-9C72-CDC548761782Q40160886-ED7BBCB3-0F7C-42D4-9AB2-6BDF8E4CDD04Q40216708-ED4D8832-363C-4A91-9212-7A9E8DE06CDEQ40386808-81D6128D-F2A2-4DB1-B3D7-5F492CECCFA1Q40671673-DAF2BDE7-01DC-4122-818B-E5DAE8330F32Q40715280-B66E15BF-6608-4F8F-B06C-F7D584FA6852Q41326571-7077652A-B89C-4518-98FF-604FBEAE17A8Q41326614-FDB7CD8C-427B-40D3-802D-E5D6BE8220DAQ41476785-BB27A1E8-5FEB-4FC0-8CF1-285B342D6641
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Veronika Bachanova
@ast
Veronika Bachanova
@en
Veronika Bachanova
@es
Veronika Bachanova
@nl
Veronika Bachanova
@sl
type
label
Veronika Bachanova
@ast
Veronika Bachanova
@en
Veronika Bachanova
@es
Veronika Bachanova
@nl
Veronika Bachanova
@sl
prefLabel
Veronika Bachanova
@ast
Veronika Bachanova
@en
Veronika Bachanova
@es
Veronika Bachanova
@nl
Veronika Bachanova
@sl
P106
P21
P31
P496
0000-0002-9325-432X